FDA Rejects Parsabiv, Amgen Has No Comment

Aug 25, 2016

The Street

Amgen announced that the FDA rejected the new drug application for Parsabiv, but the drugmaker offered no public explanation as to why the application was denied.

Parsabiv is intended for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Amgen's only public statement to the complete response letter was the following: "Amgen is reviewing the Complete Response Letter, and we anticipate a post-action meeting with the FDA later this year to discuss the Complete Response."

While not mandatory, it is still somewhat standard practice for drug companies to provide investors with a basic summary of Complete Response Letters.

Read The Street article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments